Literature DB >> 7541813

Spontaneous sustained ventricular tachycardia in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial.

K P Anderson1, R Walker, T Dustman, M Fuller, M Mori.   

Abstract

OBJECTIVES: We compared the QRS waveforms of the initial and subsequent complexes of spontaneous sustained monomorphic ventricular tachycardia and the rhythm induced at electrophysiologic study to test the theory that premature ventricular complexes "trigger" spontaneous ventricular tachycardia and that a stable substrate exists such that the spontaneous arrhythmia can be reproduced at electrophysiologic study.
BACKGROUND: Failure rates have been high in several recent studies in which prevention of ventricular tachyarrhythmias was guided by suppression of premature ventricular complexes or induced ventricular tachycardias.
METHODS: Digital waveform analysis was used to distinguish events of ventricular tachycardia initiated by configurationally distinct, possibly triggering, complexes (type 1) from events in which the initial QRS waveforms were identical to subsequent complexes, suggesting no requirement for premature ventricular beats (type 2).
RESULTS: Of 1,102 episodes of spontaneous ventricular tachycardia, 73 (6.6%) were type 1; 1,012 were type 2 (91.8%); and 17 (1.5%) were uncertain. Of 59 patients only 14 (24%) had only type 1 episodes (group 1), whereas 37 patients (63%) had predominantly type 2 events (group 2) (p < 0.0001). Sustained ventricular tachycardia was inducible in all group 1 patients, and in most (57%) the induced rhythm was similar to the spontaneous rhythm. Ventricular tachycardia could not be induced in 7 patients from group 2 (19%), and in 18 patients (49%) the induced and spontaneous rhythms were dissimilar. Recurrence of arrhythmia rates differed according to the guidance method in group 2.
CONCLUSIONS: Discrepancies between observed and predicted modes of initiation of ventricular tachycardia and between spontaneous and induced rhythms could result in inappropriate guidance and subsequent failure of antiarrhythmic treatment.

Entities:  

Mesh:

Year:  1995        PMID: 7541813     DOI: 10.1016/0735-1097(95)80027-e

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  Rate-dependent action potential alternans in human heart failure implicates abnormal intracellular calcium handling.

Authors:  Jason D Bayer; Sanjiv M Narayan; Gautam G Lalani; Natalia A Trayanova
Journal:  Heart Rhythm       Date:  2010-04-08       Impact factor: 6.343

2.  Mode of onset of polymorphic ventricular tachycardia in acute myocardial infarction.

Authors:  Bulent Gorenek; Osman Cengiz; Gulmira Kudaiberdieva; Ilker Durak; Volkan Dogan; Binnur Yasar; Alparslan Birdane; Yuksel Cavusoglu; Necmi Ata
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

Review 3.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

4.  Action potential dynamics explain arrhythmic vulnerability in human heart failure: a clinical and modeling study implicating abnormal calcium handling.

Authors:  Sanjiv M Narayan; Jason D Bayer; Gautam Lalani; Natalia A Trayanova
Journal:  J Am Coll Cardiol       Date:  2008-11-25       Impact factor: 24.094

5.  The roles of mid-myocardial and epicardial cells in T-wave alternans development: a simulation study.

Authors:  D Janusek; J Svehlikova; J Zelinka; W Weigl; R Zaczek; G Opolski; M Tysler; R Maniewski
Journal:  Biomed Eng Online       Date:  2018-05-08       Impact factor: 2.819

6.  Nighttime instabilities of neurophysiological, cardiovascular, and respiratory activity: integrative modeling and preliminary results.

Authors:  Vladimir Shusterman; William C Troy; Medhat Abdelmessih; Stacy Hoffman; Jan Nemec; Patrick J Strollo; Barry London; Rachel Lampert
Journal:  J Electrocardiol       Date:  2015-08-05       Impact factor: 1.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.